Renal insufficiency is a risk factor for cardiac implantable electronic device (CIED) infection. : A comprehensive search was conducted from multiple electronic databases to identify studies. Using the random effects model, we calculated the pooled rates of CIED infection and their 95% confidence intervals.
View Article and Find Full Text PDFPeople with sickle cell disease experience a high incidence of chronic kidney disease and end-stage kidney disease, secondary to tubular and glomerular effects of vaso-occlusion-induced hypoxia. Because of concerns of suboptimal kidney function, sickle cell donors are usually not considered for kidney donation, even if the rest of the parameters are acceptable for organ donation. A significant gap exists between the number of organ donors and the number of candidates waiting for a kidney transplant in the United States.
View Article and Find Full Text PDFBoth C-anti-neutrophil cytoplasmic antibody (ANCA) and P-ANCA vasculitis were reported to be associated with COVID-19 infection. The ideal management of COVID-19-associated ANCA vasculitis is unclear, as the experiences were limited to case reports. We presented a case of COVID-19-associated C-ANCA vasculitis, successfully treated with steroids and rituximab therapy without any significant adverse reactions.
View Article and Find Full Text PDF: Patients with infective endocarditis (IE) are more susceptible to acute kidney injury (AKI). The presence of AKI increases in-hospital complications in these patients. : The 2016-2020 National Inpatient Sample (NIS) database consisting of adult admissions with IE and AKI was utilized.
View Article and Find Full Text PDFCystinuria is an autosomal recessive disorder associated with defective proximal tubular reabsorption of divalent amino acids. It leads to increased cystine, ornithine, lysine, and arginine excretion in the urine. Cystine is insoluble in physiological pH, and cystinuria leads to crystalluria and nephrolithiasis.
View Article and Find Full Text PDFSodium-glucose cotransporter-2 inhibitors (SGLT2i) are a relatively newer class of medications, approved by the U.S. Food and Drug Administration in 2013 to treat type 2 diabetes mellitus.
View Article and Find Full Text PDF